2018 HESTIA 4 – A Multi-centre, Phase 1, Open-label, Single-Dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 months, with Sickle Cell Disease

Previous Post2015/2016 HESTIA 1 – Multicenter, Open-label, Randomized, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging, Phase 2 Study of Ticagrelor followed by a Double-blind, randomized, Parallel group, Placebo-controlled 4 weeks extension Phase in Pediatric Patients with Sickle Cell Disease